Asabys is a company that specializes in providing AI-driven solutions to enhance decision-making processes in various industries. The company leverages advanced analytics and machine learning algorithms to deliver insights and optimize operations for its clients.

Asabys

Asabys Partners is a venture capital firm from Barcelona investing across the board in human healthcare. We are active in the health-tech and biopharma industries and aim to invest in Spain and abroad in highly innovative and transformative technologies. We are motivated by the idea of pushing the boundaries of science and medicine. We do this through the sourcing and financing of the most disruptive technologies, and through the collaboration with the best internal and external talents of our industry. We have an entrepreneurial spirit and seek to be involved in the building and management of our companies. Not just investors, we consider ourselves as partners and collaborators to our portfolio companies.

Origo Biopharma

Barcelona Ventures

Alantra

Asabys Partners

I just registered for BIO-Europe Spring on March 18–20, 2024. Join me at the premier springtime partnering event #BioEuropeSpring https://lnkd.in/dbBYdzbn . Informa Connect

We are very proud to announce the acquisition of our portfolio company Cara Care by Mahana, becoming a global leader in the digital treatment of digestive health and other chronic conditions. The combined company operates across the United States, Germany and the United Kingdom with both FDA-cleared and digital wellness programs for IBS and Tinnitus currently prescribed or offered by thousands of healthcare providers, and an exciting pipeline to reach the millions of patients suffering from IBD, Heartburn, Celiac Disease, Pruritus and Vulvodynia.
 
Asabys Partners, who invested in Cara Care back in 2019 through its fund Sabadell Asabys I, now becomes a shareholder of Mahana, also backed by prominent investors including JAZZ Venture Partners and Lux Capital.
 
Our Partner Guillem Masferrer comments: “Cara Care has become the first and only digital therapy specialized in digestive diseases that is reimbursed by the German health system. Germany is a pioneer country in the world in applying regulation to allow healthcare professionals to prescribe and reimburse digital therapies, as long as they prove a positive impact on patients. We are very proud to see how Cara Care has become a valid solution for patients who do not have therapeutic alternatives and are very excited about the opportunity to be able to bring these therapies to a global market with the help of Mahana."

Banco Sabadell  Alantra  European Investment Fund (EIF)
https://lnkd.in/dimDfmsy

Congratulations to our porforfolio company Gradient Denervation Technologies for their Early Feasibility Study in the US. Gradient has already enrolled the first patient suffering from pulmonary hypertension due to left-sided heart disease, which currently has no approved drug or device therapy.

 https://lnkd.in/g4Qd2UTF 

I just registered for BIO-Europe Spring on March 18–20, 2024. Join me at the premier springtime partnering event #BioEuropeSpring https://lnkd.in/dN6ie4xw . Informa Connect

Today is International Women’s Day and we wanted to highlight our amazing female team. At #Asabys, we are incredibly proud of our female colleagues, portfolio entrepreneurs and executives, of their achievements and contributions to developing novel solutions that solve unmet medical needs. 
#InspireInclusion since diverse teams advance faster, and better.

#internationalwomensday2024 #IWD2024 #InvestInWomen #womeninscience #WomenInVC #inspireinclusion 

COM:ASABYS

Asabys